€ million |
|
Note |
|
2023 |
|
2022 |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Profit after tax |
|
|
|
2,834 |
|
3,339 |
||||||
Depreciation/amortization/impairment losses/reversals of impairment losses |
|
|
|
1,880 |
|
2,030 |
||||||
Changes in inventories |
|
|
|
-89 |
|
-604 |
||||||
Changes in trade accounts receivable |
|
|
|
-8 |
|
-413 |
||||||
Changes in trade accounts payable/refund liabilities |
|
|
|
-43 |
|
101 |
||||||
Changes in provisions1 |
|
|
|
188 |
|
279 |
||||||
Changes in other assets and liabilities1 |
|
|
|
-755 |
|
-445 |
||||||
Neutralization of gains/losses on disposal of fixed assets and |
|
|
|
-150 |
|
-48 |
||||||
Other non-cash income and expenses |
|
|
|
-72 |
|
21 |
||||||
Operating Cash Flow |
|
|
3,784 |
|
4,259 |
|||||||
|
|
|
|
|
|
|
||||||
Payments for investments in intangible assets |
|
|
|
-216 |
|
-275 |
||||||
Payments from the disposal of intangible assets |
|
|
|
136 |
|
38 |
||||||
Payments for investments in property, plant and equipment |
|
|
|
-1,807 |
|
-1,531 |
||||||
Payments from the disposal of property, plant and equipment |
|
|
|
19 |
|
21 |
||||||
Payments for investments in financial assets |
|
|
|
-537 |
|
-364 |
||||||
Payments for acquisitions less acquired cash and cash equivalents |
|
|
|
-12 |
|
-854 |
||||||
Proceeds from the disposal of other financial assets |
|
|
|
510 |
|
219 |
||||||
Payments for the acquisition of non-financial assets |
|
|
|
-2,494 |
|
-1,075 |
||||||
Proceeds from the disposal of non-financial assets |
|
|
|
2,511 |
|
1,077 |
||||||
Payments from divestments |
|
|
|
– |
|
4 |
||||||
Investing Cash Flow |
|
|
-1,892 |
|
-2,743 |
|||||||
|
|
|
|
|
|
|
||||||
Dividend payments to Merck KGaA shareholders |
|
|
|
-284 |
|
-239 |
||||||
Dividend payments to non-controlling interests |
|
|
|
-12 |
|
-11 |
||||||
Profit withdrawal by E. Merck KG |
|
|
|
-868 |
|
-716 |
||||||
Proceeds from new borrowings of financial debt from E. Merck KG and E. Merck Beteiligungen KG |
|
|
|
697 |
|
1,637 |
||||||
Repayment of financial debt to E. Merck KG and E. Merck Beteiligungen KG |
|
|
|
-420 |
|
-1,613 |
||||||
Payments from new borrowings of other current and non-current financial debt2 |
|
|
|
519 |
|
1,281 |
||||||
Repayment of other current and non-current financial debt2 |
|
|
|
-1,364 |
|
-1,893 |
||||||
Financing Cash Flow |
|
|
-1,732 |
|
-1,555 |
|||||||
|
|
|
|
|
|
|
||||||
Changes in cash and cash equivalents |
|
|
|
160 |
|
-39 |
||||||
Changes in cash and cash equivalents due to currency translation |
|
|
|
-31 |
|
-7 |
||||||
Cash and cash equivalents as of January 1 |
|
|
|
1,854 |
|
1,899 |
||||||
Cash and cash equivalents as of December 31 (consolidated balance sheet) |
|
|
1,982 |
|
1,854 |
|||||||
|
||||||||||||